Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | EED | O75530 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 3/20 | 0.30 |
| ▸ | NOS2 | P35228 | 3/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9921746 | 0.80 | CTSK (0.42) | CTSK | |
| SCHEMBL9921684 | 0.80 | CTSK (0.42) | CTSK | |
| SCHEMBL8237860 | 0.80 | CPN1 (0.50) | CPN1CPB2HRH3HRH4EED | |
| SCHEMBL435998 | 0.80 | CPN1 (0.50) | CPN1CPB2HRH3HRH4EED | |
| SCHEMBL9882398 | 0.80 | CPN1 (0.50) | CPN1CPB2HRH3HRH4EED | |
| SCHEMBL24843785 | 0.79 | CPN1 (0.46) | CPN1CPB2HRH3HRH4EED | |
| SCHEMBL22751974 | 0.79 | CPN1 (0.46) | CPN1CPB2HRH3HRH4EED | |
| Hydrochloric Acid SCHEMBL991509 | 0.78 | CPN1 (0.49) | CPN1CPB2HRH3HRH4EED | |
| SCHEMBL22752087 | 0.76 | CPN1 (0.44) | CPN1CPB2HRH3HRH4EED | |
| SCHEMBL18922375 | 0.76 | CPN1 (0.44) | CPN1CPB2HRH3HRH4EED |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | CPN1 3320/4885CPB2 3855/4885HRH3 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.